Genetics and pathology of pancreatic cancer.

Pancreatic cancer is the fourth leading cause of cancer death in the United States 1,2. Approximately 32 000 individuals in the USA and over 200 000 individuals worldwide die from the disease each year 1,2,3. The incidence approximates the mortality rate, which reflects the poor prognosis of pancreatic cancer. Although there have been many advances in pancreatic cancer research, the 5-year survival rate for affected patients remains under 5% 2. The aggressiveness that characterizes pancreatic cancer arises from multiple heterogeneous genetic changes that occur before the onset of clinical symptoms. Studies performed over the past decade have shed some light on the molecular and histological events that are associated with pancreatic carcinogenesis. This chapter will focus on the genetics and pathology of pancreatic ductal adenocarcinoma. Future progress in this area will hopefully lead to improved diagnostic tests, early detection, and new treatments for patients who suffer from this devastating disease.

[1]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[2]  Andrew P Feinberg,et al.  The epigenetics of cancer etiology. , 2004, Seminars in cancer biology.

[3]  Troels Z. Kristiansen,et al.  Comprehensive proteomic analysis of human pancreatic juice. , 2004, Journal of proteome research.

[4]  A. Ziegler,et al.  Prevalence of familial pancreatic cancer in Germany , 2004, International journal of cancer.

[5]  Steven Piantadosi,et al.  Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. , 2004, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  Olca Basturk,et al.  Pathologically and Biologically Distinct Types of Epithelium in Intraductal Papillary Mucinous Neoplasms: Delineation of an “Intestinal” Pathway of Carcinogenesis in the Pancreas , 2004, The American journal of surgical pathology.

[7]  K. Campbell,et al.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Updated Experience , 2004, Annals of surgery.

[8]  A. Ashworth,et al.  LKB1 Kinase: Master and Commander of Metabolism and Polarity , 2004, Current Biology.

[9]  M. Hebrok,et al.  Development and Cancer: Lessons Learned in the Pancreas , 2004, Cell cycle.

[10]  R. Hruban,et al.  Large-Scale Allelotype of Pancreaticobiliary Carcinoma Provides Quantitative Estimates of Genome-Wide Allelic Loss , 2004, Cancer Research.

[11]  R. Brand,et al.  Familial pancreatic carcinoma in Jews , 2004, Familial Cancer.

[12]  P. Peltomäki,et al.  Genotype and phenotype in hereditary nonpolyposis colon cancer: a study of families with different vs. shared predisposing mutations , 2004, Familial Cancer.

[13]  H. Lynch,et al.  Cancer risk in mismatch repair gene mutation carriers , 2004, Familial Cancer.

[14]  Christine A Iacobuzio-Donahue,et al.  Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. , 2003, Cancer research.

[15]  Albert J. Fornace,et al.  Transforming growth factor-beta-induced apoptosis is mediated by Smad-dependent expression of GADD45b through p38 activation. , 2003, The Journal of biological chemistry.

[16]  Gregory Y. Lauwers,et al.  Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis , 2003, Nature.

[17]  Yutaka Shimada,et al.  Widespread requirement for Hedgehog ligand stimulation in growth of digestive tract tumours , 2003, Nature.

[18]  Daniel Pinkel,et al.  Genomic microarrays in human genetic disease and cancer. , 2003, Human molecular genetics.

[19]  R. Hruban,et al.  BRAF and FBXW7 (CDC4, FBW7, AGO, SEL10) mutations in distinct subsets of pancreatic cancer: potential therapeutic targets. , 2003, The American journal of pathology.

[20]  Eithne Costello,et al.  Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent , 2003, The Journal of pathology.

[21]  R. Hruban,et al.  Notch mediates TGF alpha-induced changes in epithelial differentiation during pancreatic tumorigenesis. , 2003, Cancer cell.

[22]  R. Hruban,et al.  Fanconi anemia gene mutations in young-onset pancreatic cancer. , 2003, Cancer research.

[23]  Christine A Iacobuzio-Donahue,et al.  Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays. , 2003, The American journal of pathology.

[24]  B. Vogelstein,et al.  Evidence of selection for clones having genetic inactivation of the activin A type II receptor (ACVR2) gene in gastrointestinal cancers. , 2003, Cancer research.

[25]  Philippe Froguel,et al.  Intracellular retention is a common characteristic of childhood obesity-associated MC4R mutations. , 2003, Human molecular genetics.

[26]  Qi Guo,et al.  DNA microarray and cancer. , 2003, Current opinion in oncology.

[27]  Xinghua Lu,et al.  Detecting K-ras and p53 gene mutation from stool and pancreatic juice for diagnosis of early pancreatic cancer. , 2002, Chinese medical journal.

[28]  Sohn Ta.  The molecular genetics of pancreatic ductal carcinoma. , 2002 .

[29]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[30]  Rolf Jaggi,et al.  A high-resolution allelotype of B-cell chronic lymphocytic leukemia (B-CLL). , 2002, Blood.

[31]  Tatjana Crnogorac-Jurcevic,et al.  Expression profiling of microdissected pancreatic adenocarcinomas , 2002, Oncogene.

[32]  Kathleen M Murphy,et al.  Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17%. , 2002, Cancer research.

[33]  Haiyong Han,et al.  Identification of differentially expressed genes in pancreatic cancer cells using cDNA microarray. , 2002, Cancer research.

[34]  Kimberly Walter,et al.  Discovery of novel tumor markers of pancreatic cancer using global gene expression technology. , 2002, The American journal of pathology.

[35]  Leonid Kruglyak,et al.  A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. , 2002, American journal of human genetics.

[36]  R. Hruban,et al.  Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived , 2002, Oncogene.

[37]  C. Rosty,et al.  Molecular pathogenesis of pancreatic cancer. , 2002, Hematology/oncology clinics of North America.

[38]  P. Maisonneuve,et al.  Epidemiologic and etiologic factors of pancreatic cancer. , 2002, Hematology/oncology clinics of North America.

[39]  Giovanni Parmigiani,et al.  Relationships and differentially expressed genes among pancreatic cancers examined by large-scale serial analysis of gene expression. , 2002, Cancer research.

[40]  B. Alberts,et al.  The Cell Cycle and Programmed Cell Death , 2002 .

[41]  R. Hruban,et al.  Exploring the host desmoplastic response to pancreatic carcinoma: gene expression of stromal and neoplastic cells at the site of primary invasion. , 2002, The American journal of pathology.

[42]  T. Sohn.  The molecular genetics of pancreatic ductal carcinoma. , 2002, Minerva Chirurgica.

[43]  R. Hruban,et al.  Familial pancreatic cancer. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[44]  J. Cameron,et al.  Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  S. Leach,et al.  Lineage Commitment and Cellular Differentiation in Exocrine Pancreas , 2001, Pancreatology.

[46]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[47]  T. Brentnall,et al.  Inherited Pancreatic Cancer: Surveillance and Treatment Strategies for Affected Families , 2001, Pancreatology.

[48]  K. Lillemoe,et al.  Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Increasingly Recognized Clinicopathologic Entity , 2001, Annals of surgery.

[49]  L. Kricka,et al.  Microarray technology and applications: an all-language literature survey including books and patents. , 2001, Clinical chemistry.

[50]  S. Leach,et al.  Developmental aspects of early pancreatic cancer. , 2001, Cancer journal.

[51]  G. Riggins,et al.  Gene discovery using the serial analysis of gene expression technique: implications for cancer research. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Cameron,et al.  Discovery of new markers of cancer through serial analysis of gene expression: prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. , 2001, Cancer research.

[53]  R H Hruban,et al.  Pancreatic Intraepithelial Neoplasia: A New Nomenclature and Classification System for Pancreatic Duct Lesions , 2001, The American journal of surgical pathology.

[54]  G. Stark,et al.  Regulation of the G2/M transition by p53 , 2001, Oncogene.

[55]  J. Cameron,et al.  Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[56]  T. Mattfeldt,et al.  A murine tumor progression model for pancreatic cancer recapitulating the genetic alterations of the human disease. , 2001, Genes & development.

[57]  E. Friedman,et al.  The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel , 2001, British Journal of Cancer.

[58]  S. K. Kim,et al.  Intercellular signals regulating pancreas development and function. , 2001, Genes & development.

[59]  N. Gruis,et al.  Risk of developing pancreatic cancer in families with familial atypical multiple mole melanoma associated with a specific 19 deletion of p16 (p16‐Leiden) , 2000, International journal of cancer.

[60]  Y. Yuasa.  [Hereditary nonpolyposis colorectal cancer]. , 2000, Nihon rinsho. Japanese journal of clinical medicine.

[61]  L. Aaltonen,et al.  Population-based molecular detection of hereditary nonpolyposis colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  R. Hruban,et al.  Genetic progression in the pancreatic ducts. , 2000, The American journal of pathology.

[63]  Olfert Landt,et al.  Mutations in the gene encoding the serine protease inhibitor, Kazal type 1 are associated with chronic pancreatitis , 2000, Nature Genetics.

[64]  M. Choti,et al.  Genetic, immunohistochemical, and clinical features of medullary carcinoma of the pancreas: A newly described and characterized entity. , 2000, The American journal of pathology.

[65]  C. Ulrich.  Growth factors, receptors, and molecular alterations in pancreatic cancer. Putting it all together. , 2000, The Medical clinics of North America.

[66]  N. Arens,et al.  Identification of frequent chromosomal aberrations in ductal adenocarcinoma of the pancreas by comparative genomic hybridization (CGH) , 2000, The Journal of pathology.

[67]  R. Hruban,et al.  BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. , 2000, The American journal of pathology.

[68]  R. Hruban,et al.  Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. , 2000, Cancer research.

[69]  R H Hruban,et al.  Hypermethylation of multiple genes in pancreatic adenocarcinoma. , 2000, Cancer research.

[70]  M. Washington,et al.  Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. , 1999, Gastroenterology.

[71]  M. Talamini,et al.  Pathologic examination accurately predicts prognosis in mucinous cystic neoplasms of the pancreas. , 1999, The American journal of surgical pathology.

[72]  M Dietel,et al.  Increased expression of epidermal fatty acid binding protein, cofilin, and 14‐3‐3‐σ (stratifin) detected by two‐dimensional gel electrophoresis, mass spectrometry and microsequencing of drug‐resistant human adenocarcinoma of the pancreas , 1999, Electrophoresis.

[73]  R. Hruban,et al.  Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. , 1999, The American journal of pathology.

[74]  G. Klöppel,et al.  The K‐ras mutation pattern in pancreatic ductal adenocarcinoma usually is identical to that in associated normal, hyperplastic, and metaplastic ductal epithelium , 1999, Cancer.

[75]  P. Meltzer,et al.  Specific chromosomal aberrations and amplification of the AIB1 nuclear receptor coactivator gene in pancreatic carcinomas. , 1999, The American journal of pathology.

[76]  B. Gudjonsson.  Periampullary adenocarcinoma: analysis of 5-year survivors. , 1999, Annals of surgery.

[77]  H. Olsson.  Cancer risks in BRCA2 mutation carriers. , 1999, Journal of the National Cancer Institute.

[78]  R. Hruban,et al.  Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. , 1998, Cancer research.

[79]  R. Kuick,et al.  Amplification of DNA sequences from chromosome 19q13.1 in human pancreatic cell lines. , 1998, Genomics.

[80]  J. Yokota,et al.  Molecular karyotype (amplotype) of metastatic colorectal cancer by unbiased arbitrarily primed PCR DNA fingerprinting. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[81]  R. Hruban,et al.  Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. , 1998, Cancer research.

[82]  R. Hruban,et al.  Pathology of cancer of the pancreas. , 1998, Surgical oncology clinics of North America.

[83]  B Johansson,et al.  Comparative genomic hybridization reveals frequent gains of 20q, 8q, 11q, 12p, and 17q, and losses of 18q, 9p, and 15q in pancreatic cancer , 1997, Genes, chromosomes & cancer.

[84]  C. Moskaluk,et al.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. , 1997, Cancer research.

[85]  C. Moskaluk,et al.  p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. , 1997, Cancer research.

[86]  Steven Gallinger,et al.  Germline BRCA2 6174delT mutations in Ashkenazi Jewish pancreatic cancer patients , 1997, Nature Genetics.

[87]  E. Dimagno,et al.  Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. , 1997, Journal of the National Cancer Institute.

[88]  C. Moskaluk,et al.  Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. , 1996, Cancer research.

[89]  M. Gorry,et al.  Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene , 1996, Nature Genetics.

[90]  D. L. Sobin,et al.  Histological Typing of Tumours of the Exocrine Pancreas , 1996, World Health Organization International Histological Classification of Tumours.

[91]  Scott E. Kern,et al.  DPC4, A Candidate Tumor Suppressor Gene at Human Chromosome 18q21.1 , 1996, Science.

[92]  L. Pradayrol,et al.  Identification of K-ras Mutations in Pancreatic Juice in the Early Diagnosis of Pancreatic Cancer , 1995, Annals of Internal Medicine.

[93]  D. Easton,et al.  Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. , 1995, American journal of human genetics.

[94]  R. Hruban,et al.  Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma , 1994, Nature Genetics.

[95]  R. Hruban,et al.  Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. , 1994, Cancer research.

[96]  R. Hruban,et al.  p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. , 1994, Cancer research.

[97]  S. Goodman,et al.  Overexpression of p53 protein in adenocarcinoma of the pancreas. , 1994, American journal of clinical pathology.

[98]  N. Pellegata,et al.  K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. , 1994, Cancer research.

[99]  S. Goodman,et al.  K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. , 1993, The American journal of pathology.

[100]  H. Elsässer,et al.  Characterization of a transglutaminase expressed in human pancreatic adenocarcinoma cells. , 1993, European journal of cell biology.

[101]  F. Real,et al.  Intermediate filaments as differentiation markers of exocrine pancreas. II. Expression of cytokeratins of complex and stratified epithelia in normal pancreas and in pancreas cancer , 1993, International journal of cancer.

[102]  G. Lauer,et al.  p53 and K-RAS alterations in pancreatic epithelial cell lesions. , 1993, Oncogene.

[103]  M. Prat,et al.  Ductal cancers of the pancreas frequently express markers of gastrointestinal epithelial cells. , 1990, Gastroenterology.

[104]  G. Fleuren,et al.  KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. , 1988, Nucleic acids research.

[105]  D. Shibata,et al.  Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes , 1988, Cell.

[106]  A J Krush,et al.  Increased risk of cancer in the Peutz-Jeghers syndrome. , 1987, The New England journal of medicine.

[107]  R. Elston,et al.  Hereditary nonpolyposis colorectal cancer (lynch syndromes I and II). I. Clinical description of resource , 1985, Cancer.

[108]  P J Kumar,et al.  The Exocrine Pancreas. , 1980 .

[109]  M M Grajower,et al.  Familial pancreatic cancer. , 1983, Annals of internal medicine.